Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

UFP Technologies, Inc. UFPT

Healthcare — Medical Devices
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
13.99
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 1 — — — — 1 1 — 7 —
Insider Ownership
3.88%

Capital & Financial Ratios

Market Cap
2,140.00
Revenue
631.64
Net Income
72.30
Free Cash Flow
61.50
Net Debt
122.55
Current Ratio
3.00
Debt/Equity
0.28
P/E ratio
29.56
P/S ratio
3.39
P/B ratio
4.63
Past 5Y EPS Growth
23.59%
This Y EPS Growth
11.34%
Next Y EPS Growth
11.37%
Next 5Y EPS Growth
13.43%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 5.26 13.45 20.30 9.05
Receivables 65.75 89.66 88.22 117.37
Inventory 70.19 87.54 86.86 100.09
Other — 9.28 10.93 12.51
144.63 194.95 201.00 234.89
2023 2024 2025 Q'26
Payables 22.29 24.27 24.29 32.96
ST’ Debt 4.00 12.50 12.50 12.50
Other — 39.53 38.07 32.85
58.21 76.30 74.86 78.30
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 154.20 173.96 — —
—
’25 148.15 151.18 154.56 148.92
602.80
’24 105.01 110.18 145.17 144.07
504.42
’23 97.75 100.04 100.78 101.50
400.07
’22 71.24 94.34 96.97 91.24
353.79
’21 48.60 50.66 50.72 56.34
206.32
’20 48.28 42.64 43.30 45.15
179.37
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 3.20 15.61 — —
—
’25 13.81 25.33 35.93 16.84
91.91
’24 10.65 11.71 19.80 24.42
66.59
’23 1.72 8.88 18.03 12.70
41.33
’22 (3.22) 3.18 (0.11) 17.89
17.74
’21 3.33 6.55 3.79 0.62
14.29
’20 4.74 5.99 6.00 8.30
25.04
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 1.52 14.46 — —
—
’25 10.99 22.51 32.55 12.98
79.03
’24 8.92 8.95 14.45 21.42
53.75
’23 (0.45) 6.11 15.25 9.95
30.85
’22 (5.54) (2.99) (16.49) 35.69
10.68
’21 1.89 4.74 2.83 (0.44)
9.01
’20 3.74 4.88 5.17 6.99
20.78
in millions of $

EPS

Mar Jun Sep Dec Year
’26 2.24 2.68 — —
—
’25 2.21 2.21 2.11 2.25
8.75
’24 1.64 1.75 2.11 2.10
7.58
’23 1.27 1.55 1.52 1.51
5.83
’22 0.64 1.17 2.56 1.10
5.45
’21 0.55 0.62 0.50 0.42
2.09
’20 0.52 0.31 0.40 0.55
1.77

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 56.10 103.64 152.43 178.26 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 126.78 205.08 366.41 289.57 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,968 3,293 4,335 5,349 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.12 0.12 0.12 0.11 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 353.79 400.07 504.42 602.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.51% 28.05% 29.08% 28.27% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.72 53.90 73.03 82.51 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.90% 13.47% 14.48% 13.69% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.79 44.92 58.98 68.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.89 11.41 14.72 19.15 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 46.77 52.48 65.78 78.23 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 5.52 5.89 7.69 8.87 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.35 5.42 8.68 11.93 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.93) (1.38) (1.68) (1.67) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.41 4.05 7.01 10.26 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.40 37.53 44.70 55.01 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.56 7.62 7.67 7.71 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.94 28.16 31.80 25.03 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.47 3.16 3.72 2.84 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.68 4.42 5.47 4.04 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.61 3.23 4.09 3.05 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 86.58 41.86 38.39 23.28 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.74 41.33 66.59 91.91 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.06) (10.49) (12.85) (12.87) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.68 30.85 53.75 79.03 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.39 86.42 118.65 126.14 — — —
Working Cap'
‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55.00 32.00 201.81 149.45 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.55 26.74 188.36 129.14 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 237.55 286.09 342.76 423.88 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.73% 11.48% 11.42% 10.64% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 12.02% 11.52% 9.52% 10.44% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.35% 17.16% 18.76% 17.82% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

UFP Technologies (UFPT) exemplifies a high-growth powerhouse in the industrials sector, specializing in custom packaging and components for medical devices and aerospace. From 2016 to 2024, revenue tripled to $504 million at a 17% CAGR, propelled by strategic acquisitions like CTS and Curative Medical Packaging, amid post-COVID demand for sterile medtech solutions. This scaling quadrupled the workforce, boosted gross margins to 29.1%, and drove net income up 637% to $59 million, with EPS surging 593%—outpacing revenue thanks to operational leverage and disciplined capex.

Free cash flow per share skyrocketed 2,314% to $7.01, supporting growth while ROE exceeded 15% post-2022, and ROIC beat WACC, signaling strong value creation despite manageable post-acquisition debt. Stock lows rose 648%, with 2024 highs at $366, tracking fundamentals closely (revenue-stock correlation ~0.85), though valuation multiples like 3.7x PS and 38x EV/FCF reflect a premium for its compounding profile.

Analysts forecast 15% revenue CAGR through 2027 to $669 million, with EPS climbing to $11.43 and mean price targets implying 34% upside at ~28x forward PE. While modest insider selling tempers short-term enthusiasm, UFPT’s medical-heavy mix (60%+ revenue), M&A momentum, and 20-30% annualized return potential position it as a high-conviction outperformer in fragmented markets—watch debt reduction for further confirmation.

Read full commentary →

UFP Technologies, Inc. (UFPT) Latest News

News by impact score

Fine-tune

3 Sep

4 , 6:11 AM
UFP Technologies reported record profits, but margin performance introduced complicating factors that temper the overall results. Record profits with margin complications represent a major earnings development likely to shift investor sentiment and stock trajectory.

28 Aug

4 www.marketbeat.com, 6:01 PM
UFP Technologies targets 12%-18% growth as its medical device M&A pipeline expands. Growth targets and expanding M&A pipeline signal major strategic moves likely to alter company trajectory.

10 Aug

3 transcript www.fool.com, 9:48 PM
UFP Technologies (UFPT) released its Q2 2026 earnings call transcript covering financial results and business outlook. Earnings call content offers performance details and guidance that can moderately shift investor views and near-term stock movement.

4 Aug

4 , 4:11 PM
UFP Technologies posted record Q2 results. Analysis indicates shares trade 8% below fair value. Record quarterly results signal stronger financial performance that can lift valuation and attract investors.

4 www.fool.com, 3:10 PM
UFP Technologies stock surges sharply on positive developments boosting investor sentiment and near-term outlook. Sharp stock rise signals major positive shift likely to alter near-term trajectory and sentiment.

3 www.marketbeat.com, 2:04 PM
UFP Technologies Q2 earnings call highlighted revenue, earnings per share, and operational updates along with forward guidance. Q2 earnings data and guidance can moderately affect near-term stock sentiment and financial outlook.

3 transcript app.moby.co, 8:30 AM
UFP Technologies, Inc. held its Q2 2026 earnings call covering financial results, operations and outlook. Quarterly earnings call provides financial metrics and guidance that typically influence short-term stock movement and sentiment.

3 Aug

4 , 5:33 PM
UFP Technologies reported strong Q2 CY2026 sales, causing its stock to soar. Strong Q2 sales directly drove a surge in UFPT stock price.

4 , 4:15 PM
UFP Technologies, Inc. announced record results for the second quarter. Record Q2 results signal strong financial performance likely to boost investor sentiment and growth trajectory.

3 , 6:45 PM
UFP Technologies (UFPT) beat Q2 earnings and revenue estimates. Beating quarterly earnings and revenue estimates typically drives short-term positive stock performance and market sentiment.

2 Aug

3 , 12:36 AM
UFP Technologies (UFPT) will report Q2 earnings results tomorrow. Quarterly earnings release may move UFPT stock price and near-term sentiment.

13 May

4 Simply Wall St., 6:14 AM
UFP Technologies, Inc. (NASDAQ:UFPT) released first-quarter earnings, with analysts sharing their views on the results. Q1 earnings release and analyst reactions directly impact UFPT's financial outlook, stock valuation, and market sentiment.

3 StockStory, 4:28 PM
Analysts posed five revealing questions during UFP Technologies’ Q1 earnings call, probing key aspects of performance, growth, and strategic outlook. Revealing analyst questions from Q1 earnings call spotlight operational insights and potential challenges affecting UFPT's financial trajectory.

6 May

3 , 11:12 AM
UFP Technologies (UFPT), classified as an industrial stock, operates primarily as a medical device manufacturer, potentially undervalued due to market misperception of its core business in high-growth healthcare sectors. Revealing UFPT's dominant medical device operations within an industrial stock label moderately influences investor sentiment and valuation without fundamentally altering core operations.

5 May

4 www.marketbeat.com, 5:07 PM
UFP Technologies reported Q1 revenue of $92.6 million, up 22% year-over-year, with EPS of $1.85 beating estimates. Gross margin expanded to 28.2%, driven by medical and friction products. Full-year guidance raised to $365-385 million revenue and $7.00-7.60 EPS. Management highlighted strong demand in defense and aviation segments. Strong Q1 beat and raised guidance signal significant acceleration in revenue growth and profitability, boosting investor confidence.

4 app.moby.co, 4:46 PM
UFP Technologies, Inc. released Q1 2026 earnings call summary highlighting financial results, strategic updates, and future outlook. Q1 earnings call summaries disclose quarterly financials, guidance, and strategic insights that significantly impact investor sentiment and stock trajectory.

4 Simply Wall St., 4:06 AM
UFPT’s MedTech segment propelled Q1 2026 earnings growth, prompting debate on whether investors should reassess the company’s core strategy amid shifting segment contributions. MedTech-led Q1 2026 earnings growth signals potential strategic pivot, significantly influencing investor sentiment and UFPT's trajectory.

4 May

4 Business Wire, 4:43 PM
UFP Technologies, Inc. (UFPT) announced strong first-quarter results. Strong Q1 results indicate robust financial performance likely to enhance investor sentiment and future market trajectory.

3 Zacks, 7:30 PM
UFP Technologies (UFPT) beat first-quarter earnings estimates. Beating Q1 earnings estimates boosts UFPT's financial performance and market sentiment moderately.

3 May

4 StockStory, 8:44 PM
UFP Technologies (UFPT) released Q1 results, delivering key financial metrics and insights for investors ahead of the earnings call. Q1 results represent a major financial update capable of significantly shifting UFPT's market performance and investor expectations.

8 Mar

4 Simply Wall St., 9:05 AM
UFP Technologies extends its deal with Intuitive, heightening customer concentration risk while amplifying upside potential amid strong growth prospects. Deal extension with key partner Intuitive Surgical drives significant revenue upside but elevates concentration risk, altering UFPT's trajectory.

26 Feb

4 www.marketbeat.com, 4:32 AM
UFP Technologies reported Q4 revenue of $92.3 million, up 18% year-over-year, with EPS of $1.80 beating estimates. Net income rose 38% to $14.1 million. Full-year revenue hit $334.7 million, up 14%. Company issued FY25 guidance projecting revenue of $405-415 million and adjusted EBITDA margin of 20-21%, driven by medical and aviation segments. Robust Q4 beat, strong full-year growth, and optimistic FY25 guidance signal major positive shift in financial trajectory and investor sentiment.

25 Feb

4 GuruFocus.com, 4:04 PM
UFP Technologies Inc (UFPT) delivered record revenue and highlighted strategic initiatives in its Q4 2025 earnings call. Record revenue and strategic initiatives represent major positive drivers for UFPT's future performance and investor sentiment.

4 app.moby.co, 8:30 AM
UFP Technologies, Inc. (UFPT) released Q4 2025 earnings call summary highlighting financial results, strategic updates, and future outlook. Q4 earnings call summary delivers key financial metrics and guidance that significantly shape investor expectations and company trajectory.

24 Feb

5 GlobeNewswire, 4:30 PM
UFP Technologies, Inc. (UFPT) announced record results for 2025. Record 2025 results demonstrate exceptional financial performance poised to redefine UFPT's competitive position and long-term prospects.

4 Zacks, 10:45 PM
UFP Technologies (UFPT) reported Q4 earnings that topped analyst estimates. Q4 earnings beat highlights strong financial performance, likely driving positive investor sentiment and stock gains.

4 Associated Press Finance, 5:30 PM
UFP Technologies, Inc. (UFPT) released Q4 earnings snapshot detailing financial results. Q4 earnings snapshots reveal key financial metrics that significantly influence stock performance and investor outlook.

3 Simply Wall St., 8:11 PM
UFP Technologies (UFPT) reported solid quarterly earnings growth, prompting a valuation assessment that highlights strong performance and potential upside. Solid earnings growth positively affects UFPT's financial performance and valuation but lacks transformative elements.

3 Simply Wall St., 12:06 PM
Steady analyst forecasts around UFP Technologies' (UFPT) Q4 2025 earnings are potentially recasting the company's growth story amid stable expectations. Steady long-term earnings forecasts may moderately influence UFPT's investor sentiment and perceived growth trajectory.

22 Feb

3 StockStory, 10:08 PM
UFP Technologies (UFPT) earnings preview identifies key metrics for investors to monitor, including revenue growth, profitability margins, guidance on medical and automotive segments, supply chain issues, and overall outlook amid economic pressures. Earnings previews shape investor expectations on financial results and guidance, moderately influencing short-term market sentiment and stock performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us